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*King’s College criteria for poor prognosis
Introduction:
Two previous studies have demonstrated a decreased mortality from 
58-80% to 37-52% for patients with late-presenting acetaminophen 
poisoning who were treated with Prescott’s N-acetylcysteine protocol. 
Since 1998, we have utilized a high dose, intravenous, variable length, 
N-acetylcysteine (HINAC) regimen for patients with acetaminophen 
poisoning.
Objective:
To describe our clinical experience of HINAC therapy for the treatment of 
late-presenting acetaminophen-poisoned patients. 
Table 1.  Intravenous N-acetylcysteine Regimens
Regimen Loading Dose (mg/kg) Maintenance Dose (mg/kg)
Current study 140 70/1° q4°until AST/ALT decrease
Prescott 1979 150
50/4°, then 100/16° or until recovery 
     from encephalopathy or death
Jessica Eygnor, DO1, Suprina Dorai, MD1; Study Investigators: Philip W. Moore, DO2; J. Ward Donovan, MD2,3; Keith K. Burkhart, MD2,3,4
Methods:
A retrospective, observational chart review of an institutionally approved 
HINAC protocol from 1998 to 2003 at two toxicology centers for 
patients with late-presenting acetaminophen poisoning. Inclusion criteria 
included HINAC administration >24 hours post-ingestion with detectable 
acetaminophen levels at >24 hours and/or initial transaminases twice the 
upper limit of normal with history of >8gms of ingested acetaminophen. 
Patients were excluded by inadequate data, dosing deviation from 
HINAC protocol >25%, and chronic ingestion (>2 ingestions, separated 
by >8 hours). Our primary outcome was death; secondary outcomes 
included liver failure (defined by transaminases >1000 IU/L), King’s College 
criteria for poor prognosis and anaphylactoid reactions. Outcomes were 
compared to previously published NAC regimens.
Conclusions:
Patients with late-presenting acetaminophen poisoning who are treated 
with HINAC have decreased mortality compared to previous studies 
(p<0.0001).   
Table 2.  Demographics of 74 patients with late-presenting acetaminophen poisoning
  Median (Range) n (%)
Age (years) 31 (1-71)  
Pediatric (age <18) 15 (20%)
Gender, female 49 (66%)
History of hepatic disease 4 (5%)
Chronic ethanol abuse 18 (24%)
Suicidal intent 65 (88%)
Time to N-acetylcysteine (hours) 34 (24-88)
N-acetylcysteins doses received 7 (2-26)
Results:
Seventy-four patients met inclusion criteria. Forty-seven had detectable 
acetaminophen levels with median 80.5 and range 2-516 mcg/ml. Forty-
five patients had peak AST>1000 U/L. Median peak AST was 2756 U/L 
and range 18-23470 U/L. Fourteen patients met at least 1 King’s College 
criteria and there were 5 deaths (2 non-acetaminophen). Four patients 
had anaphylactoid reactions. 
Table 3.  Laboratory values of 74 patients with late-presenting acetaminophen (APAP) poisoning
Description n (%) Median (Range)
Initial serum alcohol (mg/dl) 17 (23%) 20 (1-592)
Peak AST>1000 (U/L) 45 (61%) 2756 (15-23470)
Peak ALT>1000 (U/L) 43 (58%) 3184 (11-17658)
*Peak protime >100 (secs) 2 (2.7%) 17.7 (11-148)
*Peak creatinine >3.3 (mg/dl) 16 (22%) 1.1 (0.4-13.7)
*Low pH<7.3 9 (12.1%) 7.36 (7.1-7.5)
Hypoglycemia during hospitalization 7 (9.4%)
Peak phosphorus >3.7 (mg/dl) 16 (22%) 3.3 (1-8.8)
Peak lactate >3.0 (mmol/L) 19 (26%) 3.2 (0.9-15.7)
Table 4.  Mortality Comparison
  Number of Patients Receiving N-acetylcysteins
Time (hours) to N-acetylcysteine 
Median (range) Mortality (n, %) p-value
Current study 75 34 (24-88) *5 (6.7%)  
Harrision 1990 41 17 (10-36) 15 (36.5%) p<0.0001
Keays 1991 25 53 (36-80) 13 (52%) p<0.0001
*Two of these patients were determined to have non-acetaminophen related mortality secondary 
to complications from prolonged opioid induced hypotension; one case with extensive ischemic 
bowel noted during laparotomy, and the second with hypoxic brain injury.
